The LucentAD test helps identify whether an individual with concerns about memory or thinking ability is likely or unlikely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. The test relies on quantitation of phosphorylated tau protein (p-Tau) in plasma using proprietary single molecule array (Simoa®) technology(1) which provides unprecedented sensitivity and precision for measuring low abundance proteins, such as brain-derived proteins in blood. This readily accessible, noninvasive test enables leveraging a simple blood test for a more informed initial evaluation of patients with memory concerns to help select who would be appropriate for further confirmatory testing for a final diagnosis. Download our guide to learn more.
1. Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. Published 2022